Abstract
Importance Sporadic Parkinson’s disease (PD) is the second most common neurodegenerative disease in older age. Recent studies have led to a debate regarding trends in incidence and prevalence.
Objective We aimed to investigate age-specific incidence rates of PD and possible explanations for the observed trend in Germany.
Design We studied two randomly selected longitudinal cohorts, each consisting of 250,000 individuals aged 50 and above.
Setting We started observing them at the beginning of 2004 and 2014, and followed them through the end of 2009 and 2019, respectively. We compared age-specific incidence rates for both cohorts and performed Cox regression models to calculate the hazard ratios (HR) of PD in the second period compared with the first period ten years earlier, adjusted for age, sex, and several prodromal factors, comorbidities, and risk factors of PD.
Main outcome and Measures Main outcome was the age-specific incidence trends of Parkinson’s disease (PD) in two cohorts using routine health claims data
Results For each age-group in men and women, we found lower age-specific PD incidence rates in the second period, except for the lowest age-group (50-54) in men. Cox regression analysis demonstrated an overall 20% risk reduction of PD incidence (HR=0.80, 95% confidence interval [0.75-0.86]). Mean age at diagnosis increased in men (+1.98 years) and women (+0,87 years). Stepwise adjustment for prodromal symptoms, comorbidities, and risk factors revealed a 22%-49% risk reduction of PD incidence. Sensitivity analysis considering the competing event of death showed a 48% risk reduction (HR=0.52 [0.48-0.56]), demonstrating the independence of the time trends from changes in death rates.
Conclusion Our data show that the risk of PD has decreased over time, and that this decrease is independent of factors such as changes in death rates, age structure, sex, motor and sensory impairments, sleep and psychiatric conditions, comorbidities, and specific risk factors.
Question While several studies have reported on the incidence and prevalence of PD, recent data from Germany have sparked a debate regarding the validity and interpretation of these trends. This study aims to investigate the age-specific incidence rates of Parkinson’s Disease (PD) and explore possible explanations for the observed reduced trend in Germany.
Findings We assessed data from a longitudinal cohort from 2004 to 2009 and 2014 to 2019, respectively. By comparing age-specific incidence rates between the two cohorts we reveal a consistent reduction in the age-specific incidence rates of PD in the second period compared to the first period, except for the lowest age-group (50-54)
Meaning While several studies have reported on the incidence and prevalence of PD, we identified intriguing trends that warrant further investigation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study did not receive external funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data access was legally approved by "the Wissenschaftliches Institut der Ortskrankenkassen." The study is based on anonymized retrospective administrative claims data that never involved patients directly. This falls outside the scope of the Declaration of Helsinki and did not require ethical review.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
NA